Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideABTAbbott Laboratories
FinDog View：Neutral
GILDGilead Sciences
FinDog View：Neutral
| Metric | ABT | GILD |
|---|
| Close | 106.20 | 170.68 |
| Market Cap | $184B | $213B |
| 1M | +7.46% | +14.51% |
| P/E (TTM) | 39.1 | — |
| Forward P/E | 17.6 | 22.0 |
| P/E 5-Yr Percentile | 99 | — |
| P/S | 3.8 | 7.0 |
| P/B | 3.6 | 17.9 |
| Dividend Yield | 1.98% | 3.98% |
| Latest Quarter Revenue | $11.2B | $8.3B |
| Revenue YoY | +7.8% | +6.8% |
| Gross Margin | 56.2% | 81.1% |
| Latest Quarter EPS | 0.61 | 1.94 |
| Avg Post-Earnings Move | ±1.6% | ±3.8% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | 2.71% | 2.57% |
| 90-Day Net Insider Buying | −$46.9M | −$15.9M |
ABT · Revenue, Last 8 Quarters ($B)
GILD · Revenue, Last 8 Quarters ($B)
